Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis

Abstract

Engelhart 1988 {published data only} Engelhart M. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma. British

Recent achievements in the management of Raynaud’s phenomenon

“……”

Recent achievements in the management of Raynaud’s phenomenon

“……”

Number needed to treat (NNT): implication in rheumatology clinical practice

“…Table 4 shows the NNTs for different drugs in patients with SSc to improve digital ulcers or patient global assessment of disease severity. [24][25][26][27] Although the NNTS calculated from certain drugs were small-for example, intravenous iloprost (NNT=1.2) 25 and ketanserin (NNT=2.3), 26 their efficacy is still inconclusive because the 95% CIs are large and include 1. Table 4 also shows the NNHs of the agents used in SSc.…”

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells

“…The adverse effects include prolonging the cardiac QT interval, inducing long QT syndrome and potentially inducing cardiac arrythmias [ 78 ]. In addition, ketanserin can induce drowsiness, fatigue, headaches, sleep disturbances, lack of concentration, dyspepsia [ 79 ], and orthostatic hypotension [ 80 ]. While ketanserin does demonstrate anti-inflammatory properties and has clinical indications, its known adverse reactions would prevent the use of ketanserin as an anti-inflammatory drug.…”

Recent achievements in the management of Raynaud’s phenomenon

“……”

Number needed to treat (NNT): implication in rheumatology clinical practice

“…Table 4 shows the NNTs for different drugs in patients with SSc to improve digital ulcers or patient global assessment of disease severity. [24][25][26][27] Although the NNTS calculated from certain drugs were small-for example, intravenous iloprost (NNT=1.2) 25 and ketanserin (NNT=2.3), 26 their efficacy is still inconclusive because the 95% CIs are large and include 1. Table 4 also shows the NNHs of the agents used in SSc.…”

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells

“…The adverse effects include prolonging the cardiac QT interval, inducing long QT syndrome and potentially inducing cardiac arrythmias [ 78 ]. In addition, ketanserin can induce drowsiness, fatigue, headaches, sleep disturbances, lack of concentration, dyspepsia [ 79 ], and orthostatic hypotension [ 80 ]. While ketanserin does demonstrate anti-inflammatory properties and has clinical indications, its known adverse reactions would prevent the use of ketanserin as an anti-inflammatory drug.…”

Recent achievements in the management of Raynaud’s phenomenon

“……”

Number needed to treat (NNT): implication in rheumatology clinical practice

“…Table 4 shows the NNTs for different drugs in patients with SSc to improve digital ulcers or patient global assessment of disease severity. [24][25][26][27] Although the NNTS calculated from certain drugs were small-for example, intravenous iloprost (NNT=1.2) 25 and ketanserin (NNT=2.3), 26 their efficacy is still inconclusive because the 95% CIs are large and include 1. Table 4 also shows the NNHs of the agents used in SSc.…”

Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells

“…The adverse effects include prolonging the cardiac QT interval, inducing long QT syndrome and potentially inducing cardiac arrythmias [ 78 ]. In addition, ketanserin can induce drowsiness, fatigue, headaches, sleep disturbances, lack of concentration, dyspepsia [ 79 ], and orthostatic hypotension [ 80 ]. While ketanserin does demonstrate anti-inflammatory properties and has clinical indications, its known adverse reactions would prevent the use of ketanserin as an anti-inflammatory drug.…”